Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes.

In our effort to discover DPP-4 inhibitors with added benefits over currently commercially available DPP-4 inhibitors, MK-3102 (omarigliptin), was identified as a potent and selective dipeptidyl peptidase 4 (DPP-4) inhibitor with an excellent pharmacokinetic profile amenable for once-weekly human dosing and selected as a clinical development candidate. This manuscript summarizes the mechanism of action, scientific rationale, medicinal chemistry, pharmacokinetic properties, and human efficacy data for omarigliptin, which is currently in phase 3 clinical development.

[1]  M. Pal,et al.  Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes. , 2009, Bioorganic & medicinal chemistry.

[2]  R. Sheridan,et al.  Modeling assisted rational design of novel, potent, and selective pyrrolopyrimidine DPP-4 inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[3]  J. Kozarich,et al.  Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. , 2003, Current opinion in chemical biology.

[4]  Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. , 2004, Journal of medicinal chemistry.

[5]  A. Woods,et al.  Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. , 2005, Diabetes.

[6]  D. Moller,et al.  Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Ping Chen,et al.  Novel tetrahydropyran analogs as dipeptidyl peptidase IV inhibitors: Profile of clinical candidate (2R,3S,5R)-2- (2,5-difluorophenyl)-5-(4,6-dihydropyrrolo [3,4-c]pyrazol-5-(1H)-yl)tetrahydro-2H-pyran-3-amine (23) [corrected]. , 2013, Bioorganic & medicinal chemistry letters.

[8]  P. Collins,et al.  Purification, identification and characterisation of seprase from bovine serum. , 2004, The international journal of biochemistry & cell biology.

[9]  G. Sutherland,et al.  Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. , 2000, European journal of biochemistry.

[10]  C. Craik,et al.  Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII. , 2003, The Biochemical journal.

[11]  Nicolai Wagtmann,et al.  Identification and characterization of human DPP9, a novel homologue of dipeptidyl peptidase IV. , 2002, Gene.

[12]  J. Cramer.  A Systematic Review of Adherence With Medications for Diabetes , 2004 .

[13]  J. Healey,et al.  Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[14]  J. Holst,et al.  The incretin system and its role in type 2 diabetes mellitus , 2009, Molecular and Cellular Endocrinology.

[15]  G. Scapin,et al.  Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin. , 2007, Bioorganic & medicinal chemistry letters.

[16]  P. Brubaker.  Minireview: update on incretin biology: focus on glucagon-like peptide-1. , 2010, Endocrinology.

[17]  Masahiro Tagawa,et al.  Rate-correction technique for QT interval in long-term telemetry ECG recording in beagle dogs. , 2002, Experimental animals.

[18]  W. Sheu,et al.  Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes , 2015, Diabetes Care.